Saxagliptin and Atherosclerosis

Summary

Saxagliptin and Atherosclerosis is a clinical trial^[1].

Key Facts

• Saxagliptin and Atherosclerosis is in the country of Norway^[2].
• Saxagliptin and Atherosclerosis's instance of is recorded as clinical trial^[3].
• Saxagliptin and Atherosclerosis's start time is recorded as +2012-03-31T00:00:00Z^[4].
• Saxagliptin and Atherosclerosis's end time is recorded as +2014-02-28T00:00:00Z^[5].
• Saxagliptin and Atherosclerosis's sponsor is recorded as Oslo University Hospital^[6].
• Saxagliptin and Atherosclerosis's main subject is recorded as diabetes^[7].
• Saxagliptin and Atherosclerosis's main subject is recorded as coronary artery disease^[8].
• Saxagliptin and Atherosclerosis's main subject is recorded as atherosclerosis^[9].
• Saxagliptin and Atherosclerosis's number of participants is recorded as {'unit': '1', 'amount': '+12'}^[10].
• Saxagliptin and Atherosclerosis's title is recorded as Saxagliptin and Atherosclerosis. A Possible Role for Saxagliptin in the Prevention of Atherosclerosis Beyond Glucose Metabolism.^[11].
• Saxagliptin and Atherosclerosis's short name is recorded as SAXATH^[12].
• Saxagliptin and Atherosclerosis's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[13].
• Saxagliptin and Atherosclerosis's ClinicalTrials.gov ID is recorded as NCT01552018^[14].
• Saxagliptin and Atherosclerosis's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+80'}^[15].
• Saxagliptin and Atherosclerosis's research intervention is recorded as saxagliptin^[16].
• Saxagliptin and Atherosclerosis's clinical trial phase is recorded as phase IV clinical trial^[17].
• Saxagliptin and Atherosclerosis's study type is recorded as interventional study^[18].